# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.
Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.24) by...
Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.
FDA extends review timeline for Humacyte's FDA marketing application for its acellular tissue-engineered vessel in vascular...
Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 ...